Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation

Clinical Therapeutics

Volumn 36, Issue 2, 2014, Pages

  Lip, Gregory Y H ^a   Kongnakorn, Thitima ^b   Phatak, Hemant ^c   Kuznik, Andreas ^d   Lanitis, Tereza ^e   Liu, Larry Z ^b,h   Iloeje, Uchenna ^f   Hernandez, Luis ^b   Dorian, Paul ^g  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b EVIDERA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

^e EVIDERA   (United Kingdom)

^f ALEXION PHARMACEUTICALS   (United States)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

apixaban; atrial fibrillation; cost effectiveness; Key word; new oral anticoagulant; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SENSITIVITY ANALYSIS; TREATMENT WITHDRAWAL; UNITED KINGDOM;

APIXABAN; ATRIAL FIBRILLATION; COST-EFFECTIVENESS; NEW ORAL ANTICOAGULANT; STROKE PREVENTION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MORPHOLINES; PYRAZOLES; PYRIDONES; STROKE; THIOPHENES; TREATMENT OUTCOME;

EID: 84894069734     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.12.011     Document Type: Article

References (58)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
2. N. Riva, and G.Y. Lip A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long term prevention of thromboembolic complications in patients with atrial fibrillation? Pol Arch Med Wewn 122 2012 45 53
3. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867 (Pubitemid 351650486)
4. I.M. Ogilvie, N. Newton, and S.A. Welner et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 123 2010 638 645 e4
5. V. Prasad, R.M. Kaplan, and R.S. Passman New frontiers for stroke prevention in atrial fibrillation Cerebrovasc Dis 33 2012 199 208
6. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
7. M.R. Patel, K.W. Mahaffey, and J. Garg et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
8. European Medicines Agency (EMA). Eliquis: EPAR-Product information - EMEA/H/C/002148 -PSUV/0012. 2013. http://www.ema.europa.eu/ema/. Accessed August 6, 2013.
9. C.B. Granger, J.H. Alexander, and J.J. McMurray et al. Aristotle Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
10. A.J. Camm, G.Y. Lip, and R. De Caterina et al. 2012 Focused dpdate of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
11. R. De Caterina, S. Husted, and L. Wallentin et al. Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper J Am Coll Cardiol 59 2012 1413 1425
12. A. Briggs, and M. Sculpher An introduction to Markov modelling for economic evaluation Pharmacoeconomics 13 1998 397 409 (Pubitemid 28140699)
13. J.V. Freeman, R.P. Zhu, and D.K. Owens et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 2011 1 11
14. H. Kamel, J.D. Easton, S.C. Johnston, and A.S. Kim Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation Neurology 79 2012 1428 1434
15. H. Kamel, S.C. Johnston, J.D. Easton, and A.S. Kim Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack Stroke 43 2012 881 883
16. S. Lee, M.W. Anglade, and D. Pham et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation Am J Cardiol 110 2012 845 851
17. S. Lee, R. Mullin, J. Blazawski, and C.I. Coleman Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation PLoS One 7 2012 e47473
18. S.V. Shah, and B.F. Gage Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Circulation 123 2011 2562 2570
19. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105:908-919.
20. D. Coyle, K. Coyle, and C. Cameron et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation Value Health 16 2013 498 506
21. A.R. Harrington, E.P. Armstrong, P.E. Nolan Jr, and D.C. Malone Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Stroke 44 2013 1676 1681
22. J. Pink, M. Pirmohamed, and D.A. Hughes Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation Clin Pharmacol Ther 94 2013 269 276
23. U. Siebert, O. Alagoz, and A.M. Bayoumi et al. Modeling Good Research Practices Task Force. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 3 Value Health 15 2012 812 820
24. J. Bamford, P. Sandercock, and M. Dennis et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project - 1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage J Neurol Neurosurg Psychiatry 53 1990 16 22 (Pubitemid 20034358)
25. European Medicines Agency (EMA). Pradaxa: EPAR-Product information - EMEA/H/C/000829 -PSU/0034. 2013. http://www.ema.europa.eu/ema/. Accessed August 6, 2013.
26. European Medicines Agency (EMA). Xarelto: EPAR-Product information - EMEA/H/C/000944 -II/0023. 2013. http://www.ema.europa.eu/ema/. Accessed August 6, 2013.
27. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691 (Pubitemid 27341818)
28. DO Claassen, N Kazemi, and AY Zubkov et al. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage Arch Neurol 65 2008 1313 1318
29. S.V. Sorensen, S. Dewilde, and D.E. Singer et al. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation Am Heart J 157 2009 1064 1073
30. S.J. Connolly, J. Eikelboom, and C. Joyner et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
31. R. Pisters, D.A. Lane, and F. Marin et al. Stroke and thromboembolism in atrial fibrillation Circ J 76 2012 2289 2304
32. M.J. Ariesen, S.P. Claus, G.J. Rinkel, and A. Algra Risk factors for intracerebral hemorrhage in the general population: a systematic review Stroke 34 2003 2060 2065 (Pubitemid 36944806)
33. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
34. J.D. Easton, R.D. Lopes, and M.C. Bahit et al. ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the Aristotle trial Lancet Neurol 11 2012 503 511
35. P. Scarborough, P. Bhatnagar, and K. Wickramasinghe et al. Coronary Heart Disease Statistics Edition 2010 British Heart Foundation London, UK
36. Human Mortality Database. 2009 UK life tables. http://www.mortality.org/ cgi-bin/hmd/country.php?cntr=GBR&level=2. Accessed July 29, 2013.
37. P.W. Sullivan, J.F. Slejko, M.F. Sculpher, and V. Ghushchyan Catalogue of EQ-5D scores for the United Kingdom Med Decis Making 31 2011 800 804
38. B.F. Gage, A.B. Cardinalli, and D.K. Owens The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life Arch Intern Med 156 1996 1829 1836 (Pubitemid 26295228)
39. L Friberg, N Hammar, and H Pettersson et al. Increased mortality in 28. Claassen DO, Kazemi N, Zubkov AY, et al. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage Arch Neurol 65 2008 1313 1318
40. L Friberg, N Hammar, and H Pettersson et al. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF) Eur Heart J 28 2007 2346 2353 (Pubitemid 47537782)
41. KF Huybrechts, JJ Caro, and J. Xenakis The prognostic value of the modified rankin scale score for long-term survival after first-ever stroke Cerebrovasc Dis 26 2008 381 387
42. KM Henriksson, B Farahmand, and S Johansson et al. Survival after stroke - the impact of CHADS2 score and atrial fibrillation Int J Cardiol 141 2010 18 23
43. H Brønnum-Hansen, M Davidsen, and P. Thorvaldsen Long-term survival and causes of death after stroke Stroke. J Cerebral Circ 32 2001 2131 2136 (Pubitemid 32868112)
44. H Bronnum-Hansen, T Jorgensen, and M Davidsen et al. Survival and cause of death after myocardial infarction: the Danish MONICA study J Clin Epidemiol 54 2001 1244 1250 (Pubitemid 34002977)
45. S Stewart, CL Hart, and DJ Hole et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study Am J Med 113 2002 359 364 (Pubitemid 35223606)
46. National Institute for Health and Clinical Excellence (January 2009) The guidelines manual.London: National Institute for Health and Clinical Excellence. www.nice.org.uk. Accessed January 21, 2014.
47. National Health Service (NHS). Electronic Drug Tariff. NHS Business Services Authority, NHS Prescription Services; 2011 http://www.ppa.org.uk/ppa/ edt-intro.htm. Accessed July 29, 2013.
48. Department of Health, National Schedule of Reference Costs Year: '2009-10' - NHS Trusts and PCTs combined. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-131140. Accessed February 11, 2013.
49. P Youman, K Wilson, and F Harraf et al. The economic burden of stroke in the United Kingdom PharmacoEconomics 21 Suppl 1 2003 43 50 (Pubitemid 36332383)
50. AD Beswick, K Rees, and I Griebsch et al. Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups Health technology assessment 2004 1 152 8:iii -iv, ix-x
51. R. Boggon, G.Y. Lip, A.M. Gallagher, and T.P. van Staa Resource utilization and outcomes in patients with atrial fibrillation: a case control study Appl Health Econ Health Policy 10 2012 249 259
52. W.L. Baker, and O.J. Phung Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation Circ Cardiovasc Qual Outcomes 5 2012 711 719
53. G.Y. Lip, T.B. Larsen, F. Skjoth, and L.H. Rasmussen Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation J Am Coll Cardiol 60 2012 738 746
54. S. Mantha, and J. Ansell An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation Thromb Haemost 108 2012 476 484
55. S. Schneeweiss, J.J. Gagne, and A.R. Patrick et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation Circ Cardiovasc Qual Outcomes 5 2012 480 486
56. B.M. Psaty, and R.L. Prentice Minimizing bias in randomized trials: the importance of blinding JAMA 304 2010 793 794
57. K.F. Schulz, I. Chalmers, R.J. Hayes, and D.G. Altman Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 273 1995 408 412
58. N.J. Welton, A.E. Ades, and J.B. Carlin et al. Models for potentially biased evidence in meta-analysis using empirically based priors J Roy Statistic Soc Series A 172 2009 119 136